• Archivo
  • Fichas de Formación
  • Revisores / Comité Asesor
  • Call For Papers
EDITORIAL
DIFUSION
ANALISIS
TRIBUNA
ENTREVISTA
EXPERT REVIEW
REORTAJE
ORIGINALES
INTELLIGENCE UNIT REPORT
FICHAS DE FORMACION
The Burden of Ulcerative Colitis and Crohn’s Disease in Spain
(Vol. 11 - Número 5 de la EDS - DICIEMBRE DE 2016)
Xavier Cortés, Luis Fernández-Salazar, Lucía Márquez, Laura Ramos, Cristina Díaz Rubio, Laura Planellas y David Gasche
Crohn’s Disease and Ulcerative Colitis are associated to relevant social and individual impact in Spain due to its chronic nature and its high prevalence. Furthermore, not only healthcare costs due to both diseases are considerable, but also the indirect costs of the illnesses. The aim of the study was to estimate the burden of the illnesses in terms of costs from the Spanish Health System perspective according to the clinical practice in Spain in 2013. Secondary objectives included the estimation of the indirect costs (societal perspective) and comorbidities’ costs.
  • Almirall
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Boston Scientific
  • Bristol-Myers Squibb
  • Grunhental
  • GSK
  • IQVIA
  • Janssen
  • Merck
  • MSD
  • Oximesa
  • Pfizer
  • Roche
  • UCB
© EDS. Resvista Española de Economía de la Salud 2018. Todos los derechos reservados.
Una publicación de wecare-u. healthcare communications group
C/ Barón de la Torre, 5 - 28043 Madrid - Tel. 91 383 43 24 | CONTACTO